Aerie Pharmaceuticals (AERI)
NASDAQ:AERI

Aerie Pharma (AERI) Stock Forecast & Price Target

596 Followers
See the Price Targets and Ratings of:

AERI Analyst Ratings

Hold
1Ratings
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Aerie
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AERI Stock 12 Months Forecast

Average Price Target

Based on 1 Wall Street analysts offering 12 month price targets for Aerie Pharma in the last 3 months. The average price target is with a high forecast of and a low forecast of . The average price target represents a change from the last price of $15.25.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Citigroup
$15.25
Hold
0.00%
Upside
Downgraded
Aerie Pharmaceuticals (AERI) downgraded to Neutral from Buy at CitiCiti analyst Yigal Nochomovitz downgraded Aerie Pharmaceuticals (AERI) to Neutral from Buy with a price target of $15.25, up from $14, citing the pending acquisition by Alcon (ALC).
H.C. Wainwright
$15.25
Hold
0.00%
Upside
Downgraded
Benzingas Top Ratings Upgrades, Downgrades For August 24, 2022For Aerie Pharmaceuticals Inc AERI , HC Wainwright Co. downgraded the previous rating of Buy to Neutral. In the second quarter, Aerie Pharmaceuticals showed an EPS of $0.32, compared to $0.84 from the year-ago quarter. The current stock performance of Aerie Pharmaceuticals shows a 52-week-high of $15.21 and a 52-week-low of $4.81. Moreover, at the end of the last trading period, the closing price was at $15.16.
Stifel Nicolaus
$15.25
Hold
0.00%
Upside
Downgraded
Stifel Downgrades Aerie Pharmaceuticals to Hold, Lowers Price Target to $15.25
Truist Financial
$15.25
Hold
0.00%
Upside
Downgraded
Truist Securities Downgrades Aerie Pharmaceuticals to Hold
Cantor Fitzgerald
$15.25
Hold
0.00%
Upside
Downgraded
Cantor Fitzgerald Downgrades Aerie Pharmaceuticals to Neutral, Lowers Price Target to $15.25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AERI Financial Forecast

AERI Earnings Forecast
Next quarter’s earnings estimate for AERI is -$0.43 with a range of -$0.57 to -$0.33. The previous quarter’s EPS was -$0.27. AERI beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.54% of the time in the same period. In the last calendar year AERI has Outperformed its overall industry.
Next quarter’s earnings estimate for AERI is -$0.43 with a range of -$0.57 to -$0.33. The previous quarter’s EPS was -$0.27. AERI beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.54% of the time in the same period. In the last calendar year AERI has Outperformed its overall industry.
AERI Sales Forecast
Next quarter’s sales forecast for AERI is $38.35M with a range of $37.12M to $39.80M. The previous quarter’s sales results were $36.13M. AERI beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year AERI has Outperformed its overall industry.
Next quarter’s sales forecast for AERI is $38.35M with a range of $37.12M to $39.80M. The previous quarter’s sales results were $36.13M. AERI beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year AERI has Outperformed its overall industry.
AERI Analyst Recommendation Trends
In the current month, AERI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AERI average analyst price target in the past 3 months is ―
In the current month, AERI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AERI average analyst price target in the past 3 months is ―

AERI Stock Forecast FAQ

What is AERI’s average 12-month price target, according to analysts?
Currently, no data Available
What is AERI’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for AERI, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is AERI a Buy, Sell or Hold?
      Aerie Pharma has a conensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
        What is Aerie Pharma’s price target?
        Currently, no data Available
        What do analysts say about Aerie Pharma?
        Aerie Pharma’s analyst rating consensus is a ‘Hold. This is based on the ratings of 1 Wall Streets Analysts.

          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis